8-K
MapLight Therapeutics Reports Positive Phase 2 Results for ML-007C-MA and Provides Corporate Update
8-K
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
8-K
MapLight Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders
8-K
MapLight Therapeutics Announces Topline Results from Phase 2 IRIS Trial of ML-004 in Autism Spectrum Disorder
8-K
MapLight Therapeutics Announces Departure of CFO Vishwas Setia
8-K
MapLight Therapeutics Reports Q1 2026 Financial Results and Clinical Progress
